Stockwinners Market Radar for September 16, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:03 EDT Cathie Wood's ARK Investment bought 139.2K shares of Reddit

19:50 EDT Purple Biotech trading halted, news pending

19:50 EDT Mullen Automotive trading halted, news pending

19:50 EDT Luokung Technology Corp trading halted, news pending

18:47 EDT Arm CEO: We're executing on our business plan and we're happy - In an interview on CNBC's Mad Money, Rene Haas said Arm has had a number of design wins in the data center over the past few years. The company has gained significant market share in the data center recently, he noted. AI workloads that require a huge amount of computing are great for Arm, he added. According to Haas, the company "is in a great place going forward."

18:03 EDT Vitesse Energy CEO buys $247K in common stock - In a regulatory filing, Vitesse Energy disclosed that its CEO Robert Gerrity bought 10K shares of common stock on September 13th in a total transaction size of $247K.

17:56 EDT Shift4 Payments general counsel Frankel sells 12,500 class A shares - In a regulatory filing, Shift4 Payments general counsel Jordan Frankel disclosed the sale of 12,500 class A common shares of the company on September 16 at a price of $82.5694 per share.

17:08 EDT Horizon Space Acquisition enters business pact with Squirrel Enlivened Intl. - Squirrel Enlivened International and Horizon Space Acquisition I announced that they have entered into an Agreement and Plan of Merger. Squirrel Cayman is a holding company of Shenzhen Squirrel Enlivened Media Group Co., Ltd. Squirrel provides brand marketing and strategy consulting solutions to brands, with a novel methodology combining rational marketing with emotional marketing. Squirrel helps brands expand and grow their businesses by providing a combination of brand marketing solutions, including digital marketing, blockbuster product development, and brand image enhancement, as well as strategy consulting solutions. It harnesses the power of technology, innovation and creation to drive significant business growth for a wide array of blue-chip and start-up companies in China. Upon the completion of the business combination of Squirrel Cayman and HSPO and related transactions pursuant to the Business Combination Agreement, shares of Squirrel Cayman will be listed on The Nasdaq Stock Market LLC.

17:01 EDT Vertical Aerospace announces 1-for-10 reverse share split - Vertical Aerospace announced a one-for-ten reverse share split of its issued and unissued ordinary shares and preferred shares, par value $0.0001 per share. The Reverse Share Split will become effective at 4:01 p.m. Eastern Time on September 20, 2024. The Company's ordinary shares will begin trading on a split-adjusted basis when the New York Stock Exchange opens for trading on Monday, September 23, 2024 under the existing trading symbol "EVTL," but the ordinary shares will trade under a new CUSIP number, G9471C206. The Company's outstanding public warrants will continue to be traded under the symbol "EVTLW" and the CUSIP number for such public warrants will remain unchanged. The Company obtained shareholders' approval for the Reverse Share Split at a ratio of between 1-for-5 and 1-for-20 at the Company's annual general meeting of the shareholders held on September 16, 2024, with the final decision of whether to proceed with the Reverse Share Split, the effective time of the Reverse Share Split, and the final reverse share split ratio to be determined by the Company's board of directors in its sole discretion. On September 16, 2024, the Company's board of directors approved the reverse share split ratio of 1-for-10 and the Effective Date for the Reverse Share Split.

16:42 EDT Farmers & Merchants Bancorp announces new $55M share repurchase program - Farmers & Merchants Bancorp announced that, effective immediately, the company has authorized a new $55 share repurchase program through December 31, 2026. The existing $25M share repurchase program approved in November 2023 has been terminated. The company has utilized a share repurchase program for many years.

16:33 EDT Carver Bancorp names Donald Felix as President and CEO - Carver Bancorp (CARV) is pleased to announce that its Board of Directors has named Donald Felix as President and CEO of the company and Bank effective November 1, 2024. He will also serve as a member of the Carver Board. Felix is an accomplished banking executive with over 25 years of global banking and broad C-level experience. In his most recent role at Citizens Financial Group (CFG) as Executive Vice President and Head of National Banking & Expansion, MFelix drove increased profitability and grew deposits by $3B.

16:30 EDT Church & Dwight announces CEO transition - The Board of Directors of Church & Dwight announced that, after a unanimous vote of its Board of Directors, Richard Dierker, a 15-year veteran of the Company, will be promoted to President and CEO and elected to the Board of Directors effective March 31, 2025. Matthew Farrell will continue to serve as President and CEO until then, and will continue to serve as Chairman of the Board for a transition period.

16:29 EDT Genius Group will not proceed with share consolidation, cancels EGM - Genius Group announced cancellation of extra ordinary general meeting, or EGM, scheduled on September 18. Upon further deliberation and following consideration of the feedback received from certain of the company's stakeholders, the board has decided not to proceed with the proposed share consolidation for the time being. Accordingly, the Company wishes to withdraw its notice of EGM, and shareholders of the company are to note that as at the date of this announcement, the EGM that was intended to be convened on September 18 has been cancelled. Shareholders should take note that proxy forms already submitted in relation to the EGM will be cancelled.

16:23 EDT Healthcare Realty Trust announces Rob Hull as COO, departure of CFO Kris Douglas - Healthcare Realty Trust announced key leadership changes. Rob Hull will become COO, Ryan Crowley will be promoted to executive VP and chief investment officer, and Julie Wilson will become chief administrative officer. In addition, Austen Helfrich will become interim CFO, succeeding Kris Douglas, who will depart the company. These changes will be effective October 1. Healthcare Realty's board of directors has formed a search committee, led by Tom Bohjalian, to hire a permanent CFO and engaged executive search firm Ferguson Partners to assist with the process.

16:18 EDT La-Z-Boy names Stitch Fix CEO Matt Baer to board - La-Z-Boy (LZB) announced that Matt Baer has been named to the company's board of directors, effective January 1, 2025. The appointment will expand the board to 11 members. Baer is an executive who brings retail leadership experience across a variety of disciplines to the board. He currently serves as CEO of Stitch Fix (SFIX).

16:18 EDT Sigma Lithium says on track to deliver Q3 production target - Sigma Lithium says it remains on track to deliver its 3Q production target of 60,000 tonnes of Quintuple Zero Green Lithium.

16:16 EDT Community Health to acquire 10 Carbon Health Urgent Care centers in Arizona - Northwest Urgent Care, LLC, a Tucson, Arizona, subsidiary of Community Health Systems, has signed an agreement to acquire 10 Arizona urgent care centers from Carbon Health. This strategic acquisition will expand capacity and increase Northwest Healthcare's network to more than 80 sites of care when the transaction is completed in the fourth quarter of this year. Terms of the deal were not disclosed.

16:14 EDT Sigma Lithium names Rogerio Marchini as CFO - Sigma Lithium is pleased to announce the appointment of Rogerio Marchini to its senior leadership, as the new Executive Vice President of Corporate Finance and CFO. Rogerio is a prominent executive in Brazil, with a deep experience of 24+ years in finance. For the last 7 years Rogerio was the CFO of Origo, a private equity portfolio company of TPG International in the energy transition space.

16:13 EDT Intel says company more than halfway to workforce reduction target - Intel CEO Pat Gelsinger also said in a note to staff that the company is more than halfway to its workforce reduction target of roughly 15,000 by the end of the year, mostly through voluntary early retirement and separation offerings. "We still have difficult decisions to make and will notify impacted employees in the middle of October," Gelsinger said. "Additionally, we are implementing plans to reduce or exit about two-thirds of our real estate globally by the end of the year. As we continue acting with urgency to execute the plan we announced last month, we are also working to carefully manage our cash as we meaningfully improve our balance sheet and liquidity. This includes through selling part of our stake in Altera-which is something we have talked about publicly several times and has long been part of our strategy to generate proceeds for Intel on Altera's path to an IPO."

16:12 EDT SciSparc publishes patent application in collaboration with Clearmind Medicine - SciSparc (SPRC) announced that as part of its ongoing collaboration with Clearmind Medicine (CMND), the publication of an international patent application under the Patent Cooperation Treaty for the combination of Ibogaine with N-Acylethanolamines. Ibogaine is the major constituent of the root of Tabernanthe iboga, a shrub commonly found in Western and Central Africa. Ibogaine use in human clinical trials suggests efficacy in the treatment of opioid use disorder, cocaine use disorder, and other substance use disorders, suggesting that Ibogaine is a potentially useful anti-addictive agent. Under this collaboration, the SciSparc and Clearmind are researching combination therapies that integrate psychedelic molecules with the N-acylethanolamines family, including Palmitoylethanolamide. To date, thirteen patents related to this collaboration have been filed by Clearmind with the U.S. Patent and Trademark Office, as well as in several other global jurisdictions.

16:11 EDT Intel to establish Intel Foundry as independent subsidiary - Intel CEO Pat Gelsinger sent a note to staff saying that, to build on the company's progress, it intends to establish Intel Foundry as an independent subsidiary inside of Intel. This governance structure will complete the process we initiated earlier this year when the company separated the P&L and financial reporting for Intel Foundry and Intel Products. "A subsidiary structure will unlock important benefits," Gelsinger said. "It provides our external foundry customers and suppliers with clearer separation and independence from the rest of Intel. Importantly, it also gives us future flexibility to evaluate independent sources of funding and optimize the capital structure of each business to maximize growth and shareholder value creation. There is no change to our Intel Foundry leadership team, which continues to report to me. We will also establish an operating board that includes independent directors to govern the subsidiary. This supports our continued focus on driving greater transparency, optimization and accountability across the business." The CEO added that the company recently increased capacity in Europe through its fab in Ireland, which will remain its lead European hub for the foreseeable future. "We will pause our projects in Poland and Germany by approximately two years based on anticipated market demand," he added. "Malaysia remains an active design and manufacturing hub through our existing operations. We plan to complete the construction of our new advanced packaging factory in Malaysia but will align the startup with market conditions and increased utilization of our existing capacity. There are no changes to our other manufacturing locations. We remain committed to our U.S. manufacturing investments and are moving forward with our projects in Arizona, Oregon, New Mexico and Ohio. We remain well-positioned to scale up production around the world based on market demand as we grow our foundry business." Reference Link

16:08 EDT BlackRock TCP Capital chairman, CEO Vig to resign - BlackRock TCP Capital Corp. announced the following leadership transitions effective November 6, 2024: Chairman of the Board and Chief Executive Officer Rajneesh Vig will resign his position as Chairman of the Board and CEO and will continue to serve on the Company's Board of Directors until January 31, 2025 to ensure a smooth transition. Raj Vig made the decision to step back from those roles and to pursue other opportunities outside of BlackRock, Inc; President Phil Tseng will succeed Raj Vig as Chairman of the Board of Directors and Chief Executive Officer. He has also been named Co-Chief Investment Officer; Chief Operating Officer Jason Mehring will assume the role of President; Patrick Wolfe, a senior investment professional with BlackRock's US Private Capital platform, has been appointed Chief Operating Officer; Dan Worrell, a senior investment professional with BlackRock's US Private Capital platform, has been named Co-Chief Investment Officer with Phil Tseng. Rajneesh Vig, BlackRock TCP Capital Corp. Chairman and CEO, said, "It has been an honor to lead BlackRock TCPC Capital Corp. over the past several years and to play a key role in the development and growth of the firm since 2006. Having partnered closely with Phil Tseng over a long and productive time, I know our team is in great hands and positioned for the next phase of growth and success."

16:07 EDT 89bio appoints Teresa Perney as chief regulatory and quality officer - 89bio announced the appointment of Teresa Perney as chief regulatory and quality officer, effective immediately. Perney brings over 20 years of relevant experience in the biotech and pharmaceutical industry. Most recently, she was chief regulatory and quality officer at EQRx prior to its acquisition.

16:06 EDT Intel to establish Intel Foundry as independent subsidiary

16:05 EDT I-Mab presents updated Phase 1 Givastomig data at ESMO - I-Mab announced a poster presentation highlighting encouraging top-line results from its ongoing Phase 1 clinical study of givastomig, a novel first-in-class/ Claudin18.2 and 4-1BB bispecific antibody immunostimulant, in patients with advanced cancers, especially gastric cancers at the European Society for Medical Oncology Congress 2024, taking place in Barcelona, Spain. Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers expressing Claudin 18.2 at low and high levels. The recommended Phase 2 dose for givastomig was determined to be 8-12 mg/kg; givastomig was well tolerated up to the highest study doses. A Phase 1b study, evaluating givastomig in combination with standard-of-care treatment in front-line gastric cancer patients, is ongoing.

16:03 EDT OFS Credit estimates NAV per share $7.04-$7.14 as of August 31, 2024 - OFS Credit Company announced the following net asset value estimate as of August 31, 2024. Management's unaudited estimate of the range of our NAV per share of the company's common stock as of August 31, 2024 is between $7.04 and $7.14. This estimate is not a comprehensive statement of OFS's financial condition or results for the month ended August 31, 2024. This estimate did not undergo the Company's typical quarter-end financial closing procedures.

15:54 EDT Tupperware Brands drops 50% after Bloomberg report of bankruptcy plans - Tupperware Brands shares are down 60c, or 50%, to 60c heading into the close following Bloomberg's report of a planned bankruptcy filing.

14:20 EDT Cleveland-Cliffs says fully committed to Middletown, Ohio project - Cleveland-Cliffs said it remains fully committed toward the project underway at its Middletown Works integrated facility in Middletown, Ohio. As previously disclosed, Cliffs was selected for award negotiations for up to $500M in total funding from the Department of Energy toward the replacement of its Middletown blast furnace with a direct reduced iron plant and two electric melting furnaces. "The Company continues to be in active negotiations with the Department of Energy related to the award-specifc terms and conditions. Cliffs remains optimistic about receiving final approvals and proceeding with this carbon-friendly and high-return project," Cleveland-Cliffs said in a statement. The company added that the new facility is expected to reduce production costs by approximately $150 per net ton of liquid steel produced, or a $450M annual savings relative to the existing configuration. The investment will secure 2,500 jobs at Middletown Works, it said.

13:35 EDT Amazon CEO tells staff to return to office five days a week from January 2, 2025 - A message from CEO Andy Jassy was shared with Amazon employees today, which states in part: "I wanted to send a note on a couple changes we're making to further strengthen our culture and teams... Two areas that the s-team and I have been thinking about the last several months are: 1/ do we have the right org structure to drive the level of ownership and speed we desire? 2/ are we set up to invent, collaborate, and be connected enough to each other (and our culture) to deliver the absolute best for customers and the business that we can? We think we can be better on both... On the first topic, we've always sought to hire very smart, high judgment, inventive, delivery-focused, and missionary teammates. And, we have always wanted the people doing the actual detailed work to have high ownership... So, we're asking each s-team organization to increase the ratio of individual contributors to managers by at least 15% by the end of Q1 2025. Having fewer managers will remove layers and flatten organizations more than they are today... To address the second issue of being better set up to invent, collaborate, and be connected enough to each other and our culture to deliver the absolute best for customers and the business, we've decided that we're going to return to being in the office the way we were before the onset of COVID... Before the pandemic, not everybody was in the office five days a week, every week... But, before the pandemic, it was not a given that folks could work remotely two days a week, and that will also be true moving forward-our expectation is that people will be in the office outside of extenuating circumstances (like the ones mentioned above) or if you already have a Remote Work Exception approved through your s-team leader... We understand that some of our teammates may have set up their personal lives in such a way that returning to the office consistently five days per week will require some adjustments. To help ensure a smooth transition, we're going to make this new expectation active on January 2, 2025... I want to thank our leaders and support teams in advance for the work they will do to improve their org structures over the coming months. With a company of our size and complexity, the work won't be trivial and it will test our collective ability to invent and simplify when it comes to how we organize and go after the meaningful opportunities we have across all of our businesses. Having the right culture at Amazon is something I don't take for granted... I'm optimistic that these changes will better help us accomplish these goals while strengthening our culture and the effectiveness of our teams." Reference Link

13:17 EDT Affirm says now available with Apple Pay - Affirm (AFRM) announced that Affirm is now available to eligible users checking out online and in-app with Apple Pay (AAPL) on iPhone and iPad. Starting today, Apple Pay users in the U.S. can request to pay over time with Affirm, splitting eligible purchases into biweekly or monthly payments for as low as 0% APR. "We are thrilled to bring the power of Affirm to Apple Pay users in the U.S. and the retailers where they shop," said Vishal Kapoor, Affirm's Senior Vice President of Product. "This integration combines the ease, convenience and security of Apple Pay alongside the features users love in Affirm - flexibility, transparency and no late or hidden fees."

13:01 EDT VW, Wells Fargo announce vehicle purchase financing cooperation agreement - Volkswagen Financial Services (VWAGY) and Wells Fargo (WFC) announced a multi-year co-branded agreement under which Wells Fargo will be the preferred purchase financing provider for the Volkswagen, Audi, and Ducati brands in the U.S. market. This new relationship is intended to begin for Audi and VW dealers and consumers beginning in April 2025, with Ducati to follow. VWFS will continue to service existing customer contracts. Volkswagen Financial Services will continue to lead the customer experience in the U.S. market with Volkswagen, Audi, and Ducati brand partners and dealers. After this transition, VWFS will focus on consumer leasing and usage-based products, including mobility solutions, supporting Volkswagen Group's growth strategy in the U.S. "We continuously evaluate our global business to make bold decisions that best position us in each of our markets," said Pablo Di Si, President and CEO, Volkswagen Group of America. "By aligning ourselves to respond to evolving market dynamics through this partnership, we're able to more effectively support the needs of Volkswagen, Audi, and Ducati while providing tremendous opportunities for Volkswagen Financial Services in the U.S. market in the future."

12:16 EDT Greenfire Resources Ltd trading resumes

12:04 EDT Celyad appoints Matt Kane as CEO - Celyad Oncology announced Matt Kane as its new CEI, effective as of October 1st, 2024 .Until recently, he served as CEO and board member of Tune Therapeutics, an epigenetic editing biotechnology company.

12:00 EDT Studio City falls -9.2% - Studio City is down -9.2%, or -56c to $5.50.

12:00 EDT Sunlands Online rises 9.7% - Sunlands Online is up 9.7%, or 51c to $5.78.

12:00 EDT Bausch + Lomb rises 13.6% - Bausch + Lomb is up 13.6%, or $2.11 to $17.66.

11:11 EDT Ventas reaches agreement with Kindred, ScionHealth - Ventas has entered into agreements with Kindred Healthcare and its parent companies, including regarding the 23 long term acute care hospitals whose lease term is scheduled to mature on April 30, 2025 under the existing Master Lease between Ventas and Kindred. The transactions under the 2024 Kindred Agreements are intended to enhance the facility environment for patient care, strengthen the Kindred Master Lease, provide upside to Ventas and enable Kindred to improve its credit profile. Key terms of the 2024 Kindred Agreements are as follows: The initial annualized cash contractual base rent for the LTACs will be $80M starting May 1, 2025, consistent with the Company's previously announced expectations, and rent will escalate annually by 2.75% through the extended lease maturity date of April 30, 2030. Ventas also has the right to receive additional revenue-sharing rent annually if revenue at these assets exceeds certain thresholds, and ScionHealth has granted Ventas warrants for 9.9% of its common equity exercisable at the pre-transaction value of the common equity. Kindred has agreed to pay full contractual cash rent through April 2025 on the LTACs. Ventas has also acquired the real estate and related property of five performing LTAC assets for a gross purchase price of $189M. The assets will continue to be operated by Kindred and were added to the existing Kindred Master Lease for an initial 10-year term. Annual cash rent of $16M commenced immediately and will escalate annually by 2.75%. ScionHealth has agreed to use the proceeds to further improve its credit profile and for other bona fide corporate purposes. The transactions should strengthen EBITDARM to rent coverage under the Master Lease to at least 1.3x. Kindred's obligations under the Master Lease will continue to be guaranteed by ScionHealth. Ventas expects the per share aggregate non-cash impact to its 2024 Normalized FFO relating to the LTAC lease extension to be in line with its previously provided 2024 guidance, commencing in the third quarter of 2024. The annualized Normalized FFO impact of the investment in performing LTACs, funded wholly with equity, is expected to be approximately $0.01 per share. Any additional cash and GAAP impacts to the Company's 2024 Normalized FFO per share from other aspects of the transactions contemplated by the 2024 Kindred Agreements are not expected to be material.

10:54 EDT JBDI Holdings Ltd trading resumes

10:41 EDT Walgreens Boots Alliance stores to close for Thanksgiving - On Thanksgiving Day, most Walgreens locations will be closed, except for 500 Walgreens 24-hour locations, and 300 pharmacies within those locations, that will remain open on Thanksgiving to help meet the healthcare needs customers. This is the second year in a row Walgreens has chosen to close its doors on Thanksgiving to allow team members to spend more time with loved ones. A small number of Walgreens distribution centers and other sites will also continue to operate on Thanksgiving Day, including supply chain and centralized teams.

10:15 EDT EHang announces EH216-S eVTOL obtains CAVE from Brazil's ANAC - EHang announced that its EH216-S pilotless electric Vertical Take-Off and Landing aircraft system has obtained an Experimental Flight Authorization Certificate from Brazil's National Civil Aviation Agency. The Company plans to conduct test and trial flights in Brazil to demonstrate the EH216-S aircraft's intelligent flight technology and cluster management system. Following an exhaustive and diligent process comprising of thorough technical documentation review and aircraft and ground control station inspection, ANAC granted the CAVE for EH216-S in Brazil. Under ANAC's CAVE framework, EHang and its local partner and operator Gohobby will conduct comprehensive EH216-S test and trial flight campaigns in Brazil in close collaboration with ANAC and Brazil's Airspace Control Department. These initiatives aim to advance research and development of Concepts of Operations and Unmanned Aircraft Traffic Management systems and services, ensuring safe and efficient UAM deployments across Brazil.

10:09 EDT AeroVironment says protest filed with GAO challenging Army's Switchblade award - In a regulatory filing, AeroVironment said that a protest has been filed with the U.S. Government Accountability Office challenging the U.S Department of the Army's decision on August 27, 2024 to award an indefinite delivery, indefinite quantity contract with a ceiling value of $990,000,000 on a sole source basis to AeroVironment related to the company's Switchblade systems. The U.S. Army has issued a stop work order on the contract and the delivery order issued thereunder while the protest is being considered by the GAO. This stop work order does not impact any of the company's other contracts or commitments, including those related to its Loitering Munitions systems. It is currently expected that the GAO will issue a decision on the protest no later than December 16, 2024.

10:01 EDT Murano Global Investments Plc trading halted, volatility trading pause

10:00 EDT Sunlands Online rises 14.0% - Sunlands Online is up 14.0%, or 74c to $6.01.

10:00 EDT ProShares Ultra Bitcoin ETF falls -5.8% - ProShares Ultra Bitcoin ETF is down -5.8%, or -$1.36 to $21.94.

10:00 EDT Four Seasons Education falls -7.2% - Four Seasons Education is down -7.2%, or -78c to $10.00.

09:56 EDT SuperCom regains compliance with Nasdaq minimum bid price rule - SuperCom has received notice from The Nasdaq Stock Market that the Company has regained compliance with Nasdaq's minimum bid price for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2), and this matter is now closed. On September 13, 2023, Nasdaq notified the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. On September 6, 2024, Nasdaq determined that for the last 10 consecutive business days, from August 22 through September 5, 2024, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2), and Nasdaq considers this matter now closed.

09:48 EDT ProShares Ultra Bitcoin ETF falls -4.5% - ProShares Ultra Bitcoin ETF is down -4.5%, or -$1.04 to $22.26.

09:47 EDT Four Seasons Education falls -7.2% - Four Seasons Education is down -7.2%, or -78c to $10.00.

09:47 EDT Azul rises 8.3% - Azul is up 8.3%, or 23c to $3.00.

09:46 EDT Liquidia says court finds United's interference caused losses over $137M - Liquidia Corporation announced that the United States District Court for the District of New Jersey has found that the interference by United Therapeutics Corporation with the launch of generic Treprostinil Injection caused losses in excess of $137M. Treprostinil Injection is manufactured by Sandoz and was launched as the first-to-file, fully-substitutable generic treprostinil for parenteral administration in March 2019. Liquidia PAH, a wholly owned subsidiary of Liquidia, partnered with Sandoz in August 2018 on an exclusive basis to market and commercialize Treprostinil Injection. The decision arises from the lawsuit filed in April 2019 by Liquidia PAH and Sandoz against United Therapeutics and another party in the District Court of New Jersey, in which Liquidia PAH and Sandoz alleged that United Therapeutics violated the Sherman Antitrust Act of 1890, state law antitrust statutes, unfair competition statutes and a prior settlement agreement between Sandoz and United Therapeutics by taking calculated steps to restrict and interfere with the launch of generic Treprostinil Injection. Specifically, Liquidia PAH and Sandoz alleged that United Therapeutics and another party entered into anticompetitive agreements whereby restrictions were placed on the cartridges necessary for the subcutaneous administration of treprostinil such that they could not be used for generic Treprostinil Injection. In March 2022, the District Court issued an order granting partial summary judgment to United Therapeutics with respect to the antitrust and unfair competition claims and granting partial summary judgment to Sandoz with respect to the breach of contract claim. After a trial, the District Court determined the damages caused by the breach of contract by United Therapeutics. Although the losses were determined by the District Court to be in excess of $137M, the final damage award has yet to be determined by the District Court and will be offset by amounts that the District Court has ruled were costs avoided by Sandoz as a result of the breach, including amounts that would have been paid to Liquidia. The District Court's decisions can be appealed by any of the parties to the proceeding. Under the agreement between Sandoz and Liquidia PAH, all proceeds from the litigation will be divided evenly between Sandoz and Liquidia PAH. Under the litigation finance agreements that Liquidia PAH has entered into with Henderson SPV and PBM RG, any net proceeds received by Liquidia PAH with respect to the damage award will be divided between Henderson and PBM such that no net proceeds will be retained by Liquidia PAH.

09:41 EDT Nano Nuclear Energy Inc trading resumes

09:23 EDT Telos expands enrollment, renewal options by opening eight locations - Telos Corporation continues to expand locations to enroll consumers in the TSA PreCheck program by opening eight new locations in California, Colorado, Florida, Ohio and Texas. These locations will begin offering enrollment services today, September 16, 2024. Telos now has 115 TSA PreCheck enrollment centers open across the U.S. The launch of these new enrollment centers represents the ongoing expansion of Telos' national TSA PreCheck enrollment footprint. Throughout 2024, Telos will continue delivering convenience to consumers by launching additional locations and extended hours of operation for enrollment and renewals.

09:18 EDT Corsair Gaming to acquire Fanatec Sim Racing from Endor, terms undisclosed - Corsair announced the signing of a definitive agreement to acquire the Fanatec Sim Racing brand and all associated personnel, in an asset purchase from Endor AG. The acquisition is expected to close within the week. Located in Landshut, Germany, Fanatec Sim Racing products include force feedback steering wheels and wheelbases, pedals, shifters and other accessories for PlayStation, Xbox, and PC-based racing simulators. Endor reported that Fanatec product sales were approximately $110M for 2023.

09:11 EDT SentinelOne, Lenovo announce multi-year collaboration - SentinelOne (S) and Lenovo (LNVGY) announced a multi-year collaboration to bring AI-powered endpoint security to millions of Lenovo devices across the globe. Lenovo will include SentinelOne's Singularity Platform and generative AI capabilities in new PC shipments, as well as offer upgrades to existing customers to expand its ThinkShield security portfolio and autonomously protect devices from modern attacks.

09:11 EDT Sprout Social launches new Salesforce integration - Sprout Social (SPT) announced a new integration with Salesforce's (CRM) Agentforce assistant for Service Cloud. The integration enables Salesforce Service Cloud and Sprout Social customers to gather customer insights from social and take accelerated action to enhance customer experiences. These updates will be featured at Dreamforce 2024, where Sprout Social will be exhibiting and speaking on how to leverage AI, social data and Salesforce to drive revenue, grow and retain a loyal customer base and strengthen brand equity.

09:10 EDT Envoy Medical awarded patent for recharge system used with implantable battery - Envoy Medical announces it has been awarded another patent from the US Patent & Trademark Office for its fully implanted devices. On September 3rd, the Company was issued Patent No. 12,081,061, "Recharge System for Implantable Battery," which relates to predicting a cumulative thermal dose associated with charging an implantable rechargeable energy storage device to a fully charged state and adjusting the amount of current provided to the device during charging. In other words, this can be used to maintain a safe temperature of an implanted rechargeable battery during recharging.

09:09 EDT VivoPower secures Mpox diagnostic tests distribution heads of agreement - VivoPower International has announced a distribution heads of agreement with Sansure Biotech for the distribution and supply of Mpox diagnostic tests and detection kits to cover Singapore, Hong Kong and Australia, with other markets under consideration. This proactive initiative is part of VivoPower's business continuity planning protocols to provide preventative measures for its own team and to supply valued partners and customers in the aforementioned markets. The heads of agreement is non binding, but both parties will work towards finalising definitive documents.

09:07 EDT T2 Biosystems receives FDA clearance to market the T2Candida Panel - T2 Biosystems announced that it has received clearance from the U.S. Food and Drug Administration, FDA, to market its FDA-cleared T2Candida Panel for pediatric patients. The Company expects to immediately begin marketing and selling the T2Candida Panel under the expanded pediatric claim. "This FDA clearance marks another important milestone in our commitment to expand the clinical utility of our sepsis test panels and allows our commercial team to immediately begin marketing and selling our test to over 200 children's hospitals in the U.S.," stated John Sperzel, Chairman and CEO of T2 Biosystems. "Studies show that the T2Candida Panel detects Candida species significantly faster, and with greater sensitivity, when compared to blood culture-based diagnostics, and we believe the new pediatric testing claim will allow clinicians to improve outcomes and reduce cost by achieving faster targeted antifungal treatment for their pediatric patients."

09:06 EDT Shuttle Pharmaceuticals expands clinical trial site enrollment for Phase 2 trial - Shuttle Pharmaceuticals has entered into agreements with two additional site locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. Four of the planned six trial sites are now prepared to enroll patients in the clinical trial, including the UVA Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center, Allegheny Health Network Cancer Institute, and Miami Cancer Institute, part of Baptist Health South Florida. Ropidoxuridine is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with RT to treat brain tumors, a deadly malignancy of the brain with no known cure. Shuttle has received Orphan Drug Designation from the FDA, providing potential marketing exclusivity upon first FDA approval for the disease. The Phase 2 clinical trial will enroll patients with the most aggressive brain tumors out there - IDH wild-type, methylation negative glioblastoma. Presently, radiation is the only approved standard of care for this particular group of patients, with more than half of the patients surviving for less than 12 months after diagnosis. Shuttle Pharma's Phase 2 clinical trial will consist initially of 40 patients randomized into two different doses to determine an optimal dose. Once the Company determines the optimal dose, it will then add an additional 14 patients on the optimal dosage allowing for the achievement of statistical significance with the end point being that of survival as compared to historical controls. The Company expects the trial to be completed over a period of 18 to 24 months.

09:04 EDT SEALSQ enters collaboration to release IoT development board - SEALSQ Corp, together with Bharat Pi announced a strategic collaboration to release a new IoT development board, integrating SEALSQ's VaultIC292 chip pre-provisioned with Matter compliant certificates. This partnership aims to set a new standard for quick prototyping with security for the fast-growing smart home and Industrial IoT segments. The new IoT board, already under consideration for several Proof-of-Concept projects, is engineered for integration into IoT devices that require support for the Matter protocol. Matter is an industry-unifying standard designed to enable seamless, secure connectivity across IoT devices in both home and industrial applications. By incorporating SEALSQ's VaultIC292 secure element, the board offers cutting-edge protection for sensitive data while ensuring device integrity, fully aligning with Matter's stringent security requirements. Additionally, SEALSQ's chip comes pre-loaded with cryptographic keys and a Matter Device Attestation Certificate, generated through SEALSQ's INeS PKI-as-a-Service Solution. Customers also benefit from the option to have their DAC signed by their own Product Attestation Intermediate, providing greater flexibility and control over their security infrastructure.

09:01 EDT Lazydays announces Ronald Fleming assumed role of Interim CEO - Lazydays Holdings announced that Ronald Fleming assumed the role of Interim CEO and joined the Board of Directors on September 14, 2024. John North stepped down as CEO and member of the Board on September 13, 2024. Fleming has been a leader in the RV industry for more than 40 years. Fleming served the company most recently as Senior Vice President of Operations, overseeing operations at Lazydays until August 2023.

08:57 EDT Gevo granted U.S. patent for ethanol-to-olefin process - Gevo announced the U.S. Patent and Trademark Office has granted to Gevo, a patent for its ethanol to olefins process. This patent further cements Gevo's position as a leader in intellectual property surrounding bio-based renewable fuel and chemical production from alcohols. Gevo has been awarded U.S. Patent No. 12,043,587 B2 covering the ETO process. This patent protects the process of using certain proprietary catalyst combinations for converting ethanol into olefins. This process is designed to give best-in-class cost and yields of olefins from ethanol, with improved energy efficiency, which is intended to help to reduce the cost of biofuels and biochemicals. Olefins with three or four carbon atoms are key building blocks to produce fuels or chemicals. Existing technology makes ethylene, a 2-carbon olefin, from ethanol, and then additional steps are needed to produce the larger and more useful olefins, such as three or four carbon olefins. This patent protects Gevo's ETO process, which makes three and/or four carbon olefins in addition to ethylene from ethanol in a single step with a high degree of selectivity and control, which is critical for success. The ETO process is expected to reduce energy and capital cost because of the fewer unit operations involved; and reduce complexity of the process design. The ETO process technology can be optimized to produce fuels and/or chemicals, the latter of which has been licensed to LG Chem, under the previously disclosed joint development agreement. Together Gevo and LG Chem are working to scale up the process for chemicals.

08:55 EDT ANI Pharmaceuticals completes acquisition of Alimera Sciences - ANI Pharmaceuticals (ANIP) announced the completion of its previously announced acquisition of Alimera Sciences (ALIM). ANI continues to expect high single-digit to low double-digit accretion in 2025 adjusted non-GAAP EPS with substantial accretion thereafter. The transaction is anticipated to deliver an additional $35 - $38 million in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10 million in identified cost synergies with additional EBITDA contribution expected from accelerated growth of Cortrophin Gel within ophthalmology. ANI is maintaining its 2024 guidance for the standalone Company based on continued momentum across Cortrophin Gel and Generics and plans to provide 2024 guidance for the combined Company by no later than the Company's third quarter earnings call. Under the terms of the merger agreement, ANI acquired all of the outstanding shares of Alimera for $5.50 per share. The Company also repaid $72.5 million of Alimera debt. Alimera investors received one non-tradable contingent value right representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027. ANI recently completed an offering of $316.25 million aggregate principal amount of 2.25% convertible senior notes due September 1, 2029. The Company utilized a majority of the net proceeds as well as cash from its balance sheet to repay in full its existing senior secured term loan facility. The initial conversion price of the convertible notes is $74.11 per share. Concurrent with the convertible offering, the Company used $40.6 million of the net proceeds to enter into capped call transactions. The cap price of the capped call transactions is initially $114.02 per share, which represents a premium of 100% over the last reported sale price of the Company's common stock on August 7, 2024. The capped call transactions are expected generally to reduce the potential dilution to ANI's common stock upon any conversion of the notes up to the cap price of $114.02. To fund the acquisition of Alimera, ANI entered into a new senior secured credit agreement consisting of a $325 million delayed draw term loan facility and $75 million revolving credit facility. On September 16, 2024 the Company drew the full $325 million term loan; the $75 million revolving credit facility remains un-drawn. The Company expects these capital structure changes to reduce interest expense by approximately $39 million on an annualized basis as compared to estimated interest expense that would have been incurred if the new principal amount of debt was subject to rates that would have applied under the previous debt capital structure.

08:52 EDT Quest Diagnostics completes acquisition of certain assets from Allina Health - Quest Diagnostics announced that it has completed its previously announced acquisition of select laboratory assets from Allina Health. The goal of the transaction is to improve access to high quality and affordable laboratory services for providers and patients in Minnesota and western Wisconsin. Financial details of the transaction were not disclosed.

08:50 EDT LQR House enters marketing partnership with Florena - LQR House announces its marketing contract with Armen's Barrels LLC brand, Florena Vodka and Gin. This company signed a contract with LQR House in mid-July 2024. Now that the product is available, the campaign has launched with the goal of generating brand awareness and significantly boosting visibility through LQR House's premier online alcohol store, CWSpirits.com.

08:48 EDT Greenlane to launch fentanyl, xylazine, drink spike detection test strips line - Greenlane Holdings announced its plans to launch an all-new line of fentanyl, xylazine and drink spike detection test strips under the Safety Strips brand of drug test strips. Products will be available to order beginning September 25th via the Company's multiple online retail storefronts,as well as its wholesale portal. Shipments will commence October 1 st. In August, Greenlane announced that it has entered into a non-binding letter of intent to be the exclusive distributor in the U.S., of Safety Strips drug detection test strips. Greenlane has been a trusted partner for some of the most successful and well-known cannabis and lifestyle brands, such as Higher Standards, Marley Natural and K.Haring, providing full sales coverage, marketing, warehousing and logistics services.

08:47 EDT CSLM Acquisition Corp. files S-4 registration statement for Nasdaq listing - CSLM Acquisition Corp. announced that it has confidentially submitted a draft registration statement on Form S-4 with the SEC on September 3, 2024 relating to its previously announced proposed business combination with Fusemachines, which will result in the public listing of the newly merged companies.

08:46 EDT Cellebrite enhance investigative analytics solution with AWS - Cellebrite (CLBT) announced Pathfinder in the Cloud with Amazon (AMZN) Web Services, AWS, allowing customers to access Cellebrite's industry-leading investigative analytics solution, Pathfinder, through the secure Amazon Virtual Private Cloud. Now available for on-premises and cloud use, Pathfinder drastically reduces the hours investigators and analysts spend on cases because its artificial intelligence capabilities help to swiftly identify meaningful data and connections across multiple devices.

08:44 EDT Kratos Defense's Turbine Technologies completes ground test campaign - Kratos Defense & Security Solutions announced that Kratos Turbine Technologies has successfully completed a ground test campaign of a Cost-Optimized, Limited-Life Turbofan Engine. The engine testing was managed by the Air Force Research Laboratory, Aerospace Systems Directorate, Turbine Engine Division under the Attritable Cost Optimized Limited Life Engine Technologies program. All test plan objectives were achieved including matching pre-test predictions on thrust and fuel efficiency.

08:41 EDT Merit Medical announces findings from WRAPSODY WAVE trial - Merit Medical Systems announced positive 6-month findings from the randomized arteriovenous fistula arm of its WRAPSODY Arteriovenous Access Efficacy, WAVE, pivotal trial. The data were shown at the Cardiovascular and Interventional Radiological Society of Europe, CIRSE, during a FIRST@CIRSE presentation. Target lesion primary patency in patients treated with WRAPSODY was 27 percentage points higher than patients in the PTA cohort. The proportion of patients who experienced an adverse event was similar between cohorts.

08:40 EDT Biodexa Pharmaceuticals announces final match payment with respect to $17M grant - Biodexa Pharmaceuticals made the final match payment with respect to a $17 million grant from the Cancer Prevention Research Institute of Texas. Familial Adenomatous Polyposis is an inherited disease that causes the growth of hundreds or thousands of precancerous polyps throughout the GI tract, putting those afflicted at great risk of developing colon cancer. There is no approved therapeutic option for treating the approximately 100,000 FAP patients in the U.S. and Europe. The current standard of care is active surveillance and surgical resection of the colon and/or rectum. Results of a 12cmonth Phase 2 clinical trial of eRapa in FAP demonstrated a 17 per cent median decrease in overall polyp burden and an overall non-progression rate of 75 per cent. A Phase 3 registrational trial is expected to begin enrollment early next year.

08:39 EDT Neuronetics releases softwaare upgrades to elevate patient care - Neuronetics announced enhancements to its NeuroStar Advanced Therapy and proprietary TrakStar(R) patient data management software, introducing a range of new features aimed at improving patient communication, streamlining clinical data capture, and strengthening cybersecurity. The software updates provide practices with more robust tools to enhance patient care and streamline operations for NeuroStar practices. Key upgrades include: Enhanced Patient Communication: New CRM capabilities automate SMS and email communication, offering personalized guidance during the early stages of NeuroStar treatment. Secure insurance card uploads now streamline claims processing and reduce errors from manual entries. Additionally, multi-site practices can filter communications by location to better manage patient needs on a local scale. Expanded TrakStar Survey Options: Practices can now access a wider range of automated patient clinical surveys to monitor well-being during and after treatment, enabling additional real-time insights to provide more effective, tailored care. Advanced Clinical Data Capture: NeuroStar's internet-connected device now synchronizes critical clinical information with the TrakStar data management system, securely automating tracking and enhancing data collection accuracy. Improved Security: Proactive updates to the Operating System are part of NeuroStar's strong commitment to ensuring safe, secure, and encrypted patient data and digital communications.

08:35 EDT Altamira announces expansion of Bentrio license, distribution agreement - Altamira Therapeutics announced that its associate company Altamira Medica has agreed with its partner Nuance Pharma, Shanghai, China to extend the territory covered by their exclusive license and distribution agreement for Bentrio nasal spray by several countries across South East and East Asia. Under the amended agreement, Nuance's territory will expand from China, Hong Kong, Macau and South Korea to also include Singapore, Malaysia, Thailand, Philippines, Indonesia, Vietnam and Taiwan, with a combined population of greater than 630 million people. Nuance has been marketing Bentrio since late 2022 in Hong Kong and recently submitted the request for marketing approval for Mainland China.

08:34 EDT Clene announces it will meet in-person with FDA to discuss CNM-Au8 - Clene announced that it will meet in-person with the U.S. Food and Drug Administration, FDA, before the end of November 2024 to discuss CNM-Au8 development for ALS. The meeting will include the FDA's Director of the Office on New Drugs, the Director of the Office of Neuroscience, and the Division of Neurology 1 review team, as well as recognized key opinion leaders in ALS, biostatistics, and biomarkers. Clene is appreciative of the FDA's use of process and regulatory flexibility to obtain the best outcome for people living with ALS.

08:30 EDT Harte Hanks appoints Jason Chapman as interim global head of sales, marketing - Harte Hanks announced a leadership transition within its sales organization. Jason Chapman has been appointed as Interim Global Head of Sales and Marketing. Chapman takes over for Kelly Waller, who has stepped down as part of a planned departure due to personal reasons. Chapman brings a wealth of experience from renowned organizations such as Bain & Company, SAP SE, Skillsoft, and most recently, Infor.

08:28 EDT Coya Therapeutics announces direct CNS anti-inflammatory effect of COYA 302 - Coya Therapeutics announced the direct CNS anti-inflammatory effect of subcutaneously administered COYA 302 in a preclinical inflammatory associated mouse model of Parkinson's Disease, or PD. Coya's chief business officer and incoming CEO Arun Swaminathan, stated: "We believe that the ability of peripherally administered biologics (COYA 302) that potently and directly ameliorate the inflammatory milieu in the brain translates to strategies to suppress CNS neuro-inflammation beyond PD, including other inflammatory mediated neurodegenerative diseases such as Alzheimer's disease (AD) and Frontotemporal Dementia (FTD)." In an inflammatory mouse model of PD, subcutaneous injections of COYA 302 significantly reduced inflammation and microglial activation in nigrostriatal brain regions responsible for motor control. Microglial activation is an important mediator of PD and plays an important role in PD pathology and neurodegeneration. Microglial inhibition may hold promise as a therapeutic strategy to delay the progression of PD. Additionally, subcutaneous injections of COYA 302 resulted in reductions in astrocyte numbers and their activation in the nigrostriatal pathway. It is known that pathogenic astrocyte activation leads to neurodegeneration in PD, and mitigating its damage may be another therapeutic target. The company anticipates presenting and/or publishing these data in a peer reviewing setting.

08:26 EDT Aptevo, Alligator Bioscience announce data from Phase 1 ALG.APV-527 trial - Aptevo Therapeutics and Alligator Bioscience announced interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 for the treatment of solid tumors likely to express the tumor antigen 5T4. The results, which include clinical activity, safety, tolerability outcomes, pharmacokinetics and pharmacodynamics were presented in a poster session on Saturday, September 14, 2024, at the European Society for Medical Oncology Annual Congress in Barcelona, Spain. ALG.APV-527, is a first-in-class bispecific antibody that targets 4-1BB and the tumor antigen 5T4. The compound is being evaluated in a multi-center, dose escalation trial that has 18 patients included in the safety analysis. These patients received multiple, prior rounds of therapy for the treatment of solid tumor types. The trial is approaching full enrollment and interim results include: Clinical Activity/Efficacy: Nine of 15 efficacy evaluable patients have a best overall response to date of stable disease; The longest SD duration was in a breast cancer patient who entered the study with progressive disease, achieved stable disease and remained on study for greater than11 months. This patient successfully transitioned to a higher dose level twice; One colon cancer patient with sustained SD remains on study for more than four months. Safety and Tolerability; ALG.APV-527 demonstrated positive safety and tolerability across all cohorts; A maximum tolerated dose has not been identified; Evidence of favorable pharmacokinetics and biological activity of ALG.APV-527; ALG.APV-527 could be measured in all patients with serum concentration of ALG.APV-527 consistent with the administered dose and preclinical predictions.; Biomarker analyses confirm biological activity of ALG.APV-527 "4-1BB has been a target of interest - though with excess toxicity - for decades, and novel bispecific approaches like this will enable us to maximize anti-tumor immunity while limiting the systemic toxicity concerns that have plagued this key immune costimulatory receptor. With this backdrop, these Phase 1 interim results are very encouraging, with ALG.APV-527 showing a positive safety profile with 60% of evaluable patients achieving stable disease, meaning not progressing for variable time frames including one breast cancer patient being treated with monotherapy on study with SD for more than 11 months. We are excited to see signs of clinical activity, underscoring the potential of the drug to benefit patients with solid tumors in the clinical setting, supported by a positive safety and tolerability profile," stated Thomas Marron, MD, PhD, Professor in Immunology & Immunotherapy and in Medicine, Hematology and Medical Oncology at Icahn School of Medicine at Mount Sinai, participating Investigator of the trial.

08:23 EDT CACI to acquire Azure Summit Technology in all-cash transaction for $1.28B - CACI announced that it has entered into a definitive agreement to acquire Azure Summit Technology in an all-cash transaction for $1.28B. Azure Summit advances Department of Defense (DoD) mission outcomes with its portfolio of radio frequency technology and engineering talent focused on the electromagnetic spectrum. As a result of the $1.28B all-cash transaction, CACI expects to realize a tax benefit over the next 15 years, the present value of which is $194M. Net of the present value of the tax benefit, the effective consideration is $1.08B. The transaction is subject to regulatory approvals and customary closing conditions and is expected to close in the second quarter of fiscal year 2025.

08:22 EDT Palisade Bio launches new corporate branding - Palisade Bio announced the launch of its new corporate branding and website, palisadebio.com and reiterated its commitment to stakeholders by advancing its lead product candidate, PALI-2108. The Company's lead program, PALI-2108, is a microbiota-activated PDE4 inhibitor prodrug in development for the treatment of moderate-to-severe ulcerative colitis. Ulcerative colitis poses significant challenges for patients who need therapies that provide effective remission rates, that are non-immunosuppressive and that have improved safety profiles. Once clinical trials begin, the Company anticipates using advanced machine learning to identify patients with elevated PDE4 activity to enhance the responder population using PALI-2108 to target ulcerative colitis. By pinpointing key markers of colitis through RNA sequencing and meta-analysis, the Company will be able to identify top PDE4-effector genes, potentially enabling Palisade to predict patient responses to PDE4 inhibitors and hopefully ensure targeted, effective treatment. Additionally, the Company's platform technology provides the opportunity to expand its pipeline across immune, inflammatory and fibrotic disease, including its PALI-1908 program in preclinical development for fibro stenotic Crohn's Disease, which shares multiple synergies with the lead PALI-2108 program. In addition to the launch of its new website, the Company has released its latest corporate presentation, now available in the Investors section of the Company's website.

08:21 EDT Gibson Energy announces renewal of normal course issuer bid - Gibson Energy announced the renewal of its Normal Course Issuer Bid/ Gibson's Board of Directors has approved a renewal of the Company's NCIB, and the Toronto Stock Exchange has accepted Gibson's notice of intention to commence its NCIB for an additional one-year period. This enables the Company to purchase and cancel up to 7.5% or 9,958,026 of the public float for the issued and outstanding common shares as of September 11, 2024 over the next 12 months commencing September 18, 2024 in accordance with the applicable rules and policies of the TSX and applicable securities laws. As of September 11, 2024, the Company had 162,758,103 common shares issued and outstanding. Under the NCIB, common shares may be repurchased in open market transactions on the TSX, and/or other Canadian alternative trading platforms. In accordance with the rules of the TSX governing a NCIB, the total number of common shares the Company is permitted to purchase is subject to a daily purchase limit of 132,241 common shares, representing 25% of the average daily trading volume of common shares on the TSX calculated for the six-month period ended August 31, 2024. The NCIB will terminate at the earlier of September 17, 2025 and the date on which the maximum number of common shares that can be acquired pursuant to the NCIB have been purchased. The price that Gibson will pay for common shares in open market transactions will be the market price at the time of purchase. Gibson continues to believe that the availability of a NCIB will enable the Company to maximize return to shareholders. The actual number of common shares that may be purchased, if any, and the timing of any such purchases, will be determined by Gibson based on several factors, including the continued adherence to its Financial Governing Principles. Gibson did not purchase any common shares under its normal course issuer bid that commenced on September 15, 2023 and ended on September 14, 2024. 9,812,193 common shares were approved for purchase under the Prior NCIB.

08:20 EDT Immutep announces efficacy, safety results from TACTI-003 Phase IIb trial - Immutep announces positive efficacy and safety results from the TACTI-003 Phase IIb trial evaluating eftilagimod alpha in combination with MSD's (MRK) anti-PD-1 therapy KEYTRUDA as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients, 1L HNSCC. Efti in combination with pembrolizumab led to a 32.8% ORR in evaluable patients with CPS greater than or equal to1 compared to 26.7% for pembrolizumab in evaluable patients with CPS greater than or equal to1, according to RECIST 1.1. Imbalances of prognostic markers towards the pembrolizumab alone arm included HPV status, smoking status, and primary tumour location. Durability of response was achieved with the addition of efti with a median DOR of 17.5 months in the E+P arm. Efti in combination with pembrolizumab continues to have a favourable safety profile with no new safety signals observed.

08:18 EDT PetVivo appoints Skylor Walker as regional business development manager - PetVivo Holdings has appointed Skylor Walker to the new position of field veterinary business development manager for the entire state of Louisiana and the southern region of Texas. She previously served as a regional sales manager covering Texas, Oklahoma, New Mexico for Contura International, the maker of ArthramidVet Most recently Skylor excelled as an Associate District Manager for ADP. Walker will focus on expanding sales of PetVivo's flagship product, Spryng with OsteoCushion Technology.

08:18 EDT BOS Better Online Solutions receives an order in the amount of $900,000 - BOS Better Online Solutions announced that its Supply Chain Division has received an order in the amount of $900,000 from an Israeli customer in the aerospace industry. This order is to be delivered through 2024. Avidan Zelicovski, BOS' President, emphasized: "This significant order from a long-standing customer is a testament to the reliability and quality of BOS' supply chain services and underscores the value that they offer."

08:17 EDT Lexicon announces departure of President, COO Jeff Wade - Lexicon Pharmaceuticals announced that Jeff Wade, president and chief operating officer, COO, has decided to step down to pursue new opportunities outside of Lexicon, effective September 30, 2024. A search for a new chief financial officer is ongoing.

08:16 EDT Apollomics presents Vebreltinib data in patients with NSCLC - Apollomics announced a poster presentation at the 2024 European Society for Medical Oncology, ESMO, Congress, taking place September 13-17, 2024 in Barcelona, Spain. The poster presentation titled "Vebreltinib Efficacy and Safety in NSCLC Patients with METex14 Skipping Mutations" highlighted data from the ongoing global Phase 2 SPARTA-II trial and the Company's partner, Avistone, Phase 2/3 KUNPENG trial in China. The analysis of the data included 108 patients without prior exposure to MET inhibitors that received vebreltinib, 200 mg BID in 28-day cycle, with 12 months of follow up data. With centrally confirmed METex14 skipping, overall response rate, ORR, to vebreltinib in treatment-naive patients was 66.7% with median duration of response, DOR, of 17.3 months and median progression free survival, PFS, of 13.8 months. Treatment-related adverse events of grade 3 or higher were reported in 48.1% of patients, with the most common being edema. No death was reported due to TEAEs.

08:15 EDT Creative Media & Community Trust declares 4c per share quarterly dividend - The company further announced that its board of directors has declared a quarterly dividend of 4c per share of common stock, payable in shares of common stock. The dividend will be paid on October 8 to stockholders of record at the close of business on September 25. The number of shares of common stock payable will be determined using the closing price of the common stock on September 13.

08:14 EDT Creative Media & Community Trust to accelerate transition to multifamily assets - CMCT announced actions to accelerate the transition of its focus towards multifamily assets from traditional office assets. The company has previously targeted a capital structure consisting of approximately 40% common equity, 30% preferred equity and 30% debt. The recent decline in real estate values, particularly in the Bay Area and the office market in general, has resulted in a lower than targeted common equity ratio. CMCT recently explored the sale of several assets to improve its common equity ratio. The offer CMCT received reflected what the company believed to be the fair value of these assets, but the buyer was unable to close. As a result of this and the recent decline in interest rates, CMCT has decided to shift its focus to refinancing rather than a sale of these assets. The company intends to place property-level financing on several assets and use part of the proceeds to fully repay its recourse corporate-level credit facility. The company plans to invest any remaining proceeds, along with proceeds from any future potential asset sales, principally in premier multifamily properties. As part of its program to improve its common equity ratio, the company is suspending its Series A1 Preferred Stock offering and announcing the redemption of approximately 2.2M shares of Series A Preferred Stock and approximately 2.6M shares of Series A1 Preferred Stock, with the redemption price to be paid in shares of common stock in accordance with the terms of the Series A Preferred Stock and Series A1 Preferred Stock, respectively. The company is also shifting the payment schedule of its quarterly dividend from monthly to quarterly for all its series of outstanding preferred stock. The company's previously declared dividends on its preferred stock for the third quarter of 2024 will continue to be paid out monthly in September and October as previously announced. The company believes these actions will strengthen its balance sheet, improve liquidity and accelerate the transition towards premier multifamily properties. These actions should also better position the company to take advantage of opportunities that are expected to arise in a recovering real estate market.

08:14 EDT BioVie secures all scientific approvals needed to receive $12.6M grant funding - BioVie announced that the U.S. Army Medical Research and Development Command, Office of Human Research Oversight, OHRO, has approved BioVie's plan to evaluate bezisterim for the treatment of neurological symptoms that are associated with long COVID. FDA had previously reviewed and approved the study as Safe to Proceed in August 2024. Approval from OHRO is the last scientific review milestone needed for the Company to receive the additional $12.6 million in grant funding from the U.S. Department of Defense, DOD, and initiate Phase 2 testing in long COVID.

08:13 EDT BioAtla presented poster of Phase 2 trial data at ESMO meeting - BioAtla presented a poster of Phase 2 trial data at the European Society for Medical Oncology, ESMO, Annual Meeting. The poster presentation entitled, "Phase 2 trial of ozuriftamab vedotin, a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck," reported multiple confirmed responses among heavily pretreated patients who tolerated treatment well. The Company's novel, conditionally active anti-ROR2-ADC was recently granted FDA Fast Track Designation for treatment of patients with recurrent or metastatic SCCHN. Among 31 evaluable patients: Ten responses overall: ORR 32% across both dosing regimens; Responses and SD were observed regardless of HPV status and ROR2 expression; Overall DCR across both dosing regimens was 77%; Responses were confirmed among 6 responding patients; Median duration of response for all confirmed responders is not yet reached. Treatment with ozuriftamab vedotin was well tolerated

08:12 EDT Vuzix receives $10M first tranche investment from Quanta Computer - Vuzix is pleased to announce that it has completed the closing of the first investment tranche, for the sale of $10M in common stock at $1.30 per share, under its previously announced September 3, 2024 purchase agreement with Quanta Computer.

08:11 EDT SRx Health insiders purchase shares of Better Choice Company - Better Choice Company announced that certain board members and senior management of SRx Health Solutions Inc. have purchased 10,000 shares of Better Choice common stock. Additionally, Better Choice has activated its share repurchase program and has purchased shares in the open market.

08:10 EDT Adeia to present research on unauthorized broadband sharing - Adeia will present cutting-edge research on detecting and preventing unauthorized broadband sharing at the upcoming SCTE TechExpo24, September 24-26. The presentation, "How to Address Unauthorized Broadband Sharing," will be delivered on September 24 by Adeia's chief technology officer, Serhad Doken, who co-authored the paper together with Dr. Dhananjay Lal, vice president of advanced R&D at Adeia. With broadband providers facing an urgent and increasing challenge from password sharing, Adeia's research offers multiple innovative solutions leveraging artificial intelligence, machine learning, and advanced RF techniques. These methods help service providers protect their revenue streams while enhancing consumer cybersecurity. Key highlights of the presentation include an in-depth analysis of the broadband sharing landscape and its impact on service providers and an overview of distinct implementation methods, including clustering and machine learning algorithms for detecting suspicious accounts, Wi-Fi sensing techniques to create dynamic household maps, device ranging methods to identify out-of-home connections, attestation processes for continuous authentication, and RF signal control for precise coverage management.

08:08 EDT Icahn Enterprises says Carl Icahn 'absolutely not selling' IEP units - IEP would like to correct the record regarding the prospectus supplement that was filed recently with the SEC. Several media outlets repeated the false claim that this filing indicated an intent for Chairman Carl Icahn to sell large amounts of IEP units. To the contrary, as Mr. Icahn stated publicly, he is "absolutely not selling" IEP units. Neither is there a plan for IEP to conduct a massive sale of units, as was also reported erroneously. The filing was merely a routine refreshment of the registration statement related to our at-the-market offering program. Since the date of that filing, IEP has sold under $3.5M worth of units under the ATM program. There are no plans to conduct any offerings outside of the ordinary course and consistent with our past practices.

08:07 EDT Tactile Systems receives PDAC approval for Nimbl - Tactile Systems Technology announced that the Pricing, Data Analysis, and Coding, PDAC, contractor for the Centers for Medicare & Medicaid Services, CMS, has approved the use of Healthcare Common Procedure Coding System, HCPCS, code E0651 for billing the Durable Medical Equipment Medicare Administrative Contractors for Nimbl, the Company's next-generation pneumatic compression platform. PDAC approval is subsequent to the receipt of 510(k) clearance from the U.S. Food and Drug Administration, FDA, in June 2024. The Company will make Nimbl commercially available in the United States in the coming weeks.

08:07 EDT Icahn Enterprises says proposed class action lawsuit dismissed without prejudice - Icahn Enterprises is pleased to announce that the proposed class action lawsuit against IEP and certain directors and officers has been dismissed without prejudice. On September 13, 2024, U.S. District Court Judge Michael Moore found that the lawsuit - comprised of meritless claims cut and pasted from false and misleading reports published by Hindenburg "Research" - failed to show that IEP had made material misrepresentations or omissions or did so with an intent to defraud. Carl Icahn, Chairman of IEP, stated: "We are pleased that the spurious claims of various unscrupulous characters, working together in a coordinated and clandestine network, have been debunked. Those making these claims include short sellers who peddle false and misleading information styled as "research", their sketchy and anonymous financial backers who short securities in the shadows, thereby amplifying the disinformation campaign and profiting at the expense of long-term investors, those in the press who are used in the scheme as tools to repeat the fallacious claims, and the bottom-feeding "strike suit" lawyers who travel in their wake and attempt to extort quick settlements from victimized companies. We are also encouraged that the SEC is now beginning to take long needed action against this "short and distort" practice, which disproportionately impacts small investors. We are also happy to have recently settled the investigation initiated by the SEC following the publication of Hindenburg's false and misleading "research" report. We cooperated fully with the SEC and the SEC found no fraud, inflation of our net asset value or impropriety in our distributions, nor did it validate any of Hindenburg's other spurious claims. Instead, we settled a technical disclosure violation."

08:05 EDT Theriva Biologics awarded manufacturing funding from Spanish government - Theriva Biologics announced that the THERICEL project has been awarded funding of EUR 2.28M from the National Knowledge Transfer Program of the Spanish government's Ministry of Science, Innovation & Universities to support a collaboration between the Company and the Universitat Autonoma de Barcelona, UAB, to advance the Company's suspension cell platform for the clinical manufacture of adenovirus- and adeno-associated virus, AAV, therapies. Under the award, Theriva will receive a loan of EUR 1.33M as a lump sum payment in Q4 2024 which shall be repaid over 7 years commencing three years from the date of award and UAB will receive a grant of EUR 0.95 million dedicated to the THERICEL project and paid in annual installments over the next 3 years.

08:05 EDT Kyverna Therapeutics names Warner Biddle as CEO, succeeding Peter Maag - Kyverna Therapeutics announced the appointment of Warner Biddle as the company's CEO and a member of its Board of Directors. Biddle succeeds Peter Maag, Ph.D., who has resigned from his role as CEO and a member of the Board, effective immediately. In addition, Kyverna announced the appointment of Christi Shaw to its Board of Directors. Shaw succeeds Brian Kotzin, M.D., who has decided to step down from the Board of Directors. Biddle is a seasoned pharmaceutical executive, with over 30 years of global experience in senior commercial and franchise leadership roles across various products, disease areas and geographies. Most recently, he served as Senior Vice President, Global Head of Commercial at Kite Pharma.

08:03 EDT ChargePoint appoints David Vice as chief revenue officer - ChargePoint announced the appointment of David Vice as chief revenue officer. Vice joins the company to drive growth, overseeing the global sales and marketing functions. Prior to joining ChargePoint, he served as Chief Revenue Officer at NTT Data Services.

08:03 EDT Korro Bio announces collaboration with Novo Nordisk - Korro Bio (KRRO) announced a collaboration with Novo Nordisk (NVO) to advance the discovery and development of new genetic medicines, with the initial target to treat cardiometabolic diseases. The collaboration brings together Novo Nordisk's deep cardiometabolic disease understanding and drug development experience with Korro's proprietary platform to develop RNA editing product candidates for two undisclosed targets.

08:02 EDT Concentra opens new medical center in Chattanooga - Concentra announced the opening of a new medical center in Chattanooga, Tennessee. The medical center, Concentra Chattanooga Airport, is located at 6413 Lee Highway, Suite 107, Chattanooga, Tennessee 37421.

08:01 EDT Apollo to pay BP $1B to buy stake in TAP gas link unit - bp (BP) and Apollo (APO) announced an agreement for Apollo-managed funds to purchase a non-controlling stake in bp Pipelines TAP Limited, the bp subsidiary that holds a 20% share in Trans Adriatic Pipeline AG in a transaction valued at approximately $1B. Upon completion, bp will remain the controlling shareholder of bp Pipelines TAP Limited. "We are very pleased to come together with Apollo on this key piece of Europe's energy infrastructure. Importantly, while bringing in a new investor, this does not diminish bp's role in a strategic asset for our Azerbaijan gas business. We see great potential in building innovative arrangements such as this and look forward to continuing to explore further opportunities with Apollo through growing this collaborative relationship," said William Lin, bp EVP gas and low carbon energy. bp and Apollo will also look to partner on additional investment opportunities, including potential co-operation in both gas and low carbon energy assets, and infrastructure. The proceeds from the transaction will contribute to bp's 2024 divestment and other proceeds target of $2B-$3B, part of the company's disciplined financial frame. The transaction is expected to close in 4Q 2024, subject to customary regulatory and partner approvals required. Reference Link

08:00 EDT F&G Annuities enters strategic collaboration with Accenture - F&G Annuities announced a strategic collaboration with Accenture to enhance F&G's technology platform capabilities to optimize and scale operations for future growth through the utilization of Accenture's Life Insurance and Annuity Platform, or ALIP. F&G has embarked on a cloud modernization program.

07:38 EDT Checkpoint Therapeutics announces presentation of data on cosibelimab - Checkpoint Therapeutics announced the presentation of longer-term data from its pivotal trial of cosibelimab, its anti-programmed death ligand-1 antibody, in locally advanced and metastatic cutaneous squamous cell carcinoma during the European Society for Medical Oncology, ESMO, Congress 2024, which is taking place in Barcelona, Spain, from September 13 to 17, 2024. With 16 months of additional follow-up since the primary analysis, cosibelimab demonstrated increasing objective response rates and complete response rates per independent central review in 109 patients with advanced cSCC. Overall, in 192 advanced cSCC patients treated with cosibelimab, a manageable safety profile was observed, with notable low rates of treatment-emergent adverse events, severe immune-related adverse events, and treatment discontinuations.

07:37 EDT Psyence CEO says positioned 'to be a leader' in psychedelic-based therapeutics - CEO Neil Maresky said, in part, "It has been an eventful and productive few months since my last letter in March, and I wanted to take this opportunity to update you on our recent progress, as well as key milestones that we are focused on going forward. Beginning with our lead clinical program, which is evaluating nature-derived psilocybin in conjunction with psychotherapy as a potential treatment for Adjustment Disorder in Palliative Care, we recently announced the initiation of patient screening in our Phase IIb clinical trial that we are running in Australia. Together with our partners, Fluence and iNGENu, we will endeavor to enroll this study as efficiently as possible, and we look forward to topline data in the back half of next year that, if positive, will support the initiation of a pivotal Phase III trial as soon as practicable thereafter. We see this as a big value inflection point for our company. To better support this program, we have partnered with Optimi Health through a non-binding Letter of Intent whereby Optimi will be our exclusive supplier of GMP nature-derived psilocybin extract for both our Phase III trial as well as subsequent commercialization. This LOI gives us confidence that we will have a reliable supply of high-quality GMP nature-derived psilocybin extract as we continue to advance our Adjustment Disorder clinical program. We also announced our second development indication, which will evaluate GMP nature-derived psilocybin as a potential treatment for Substance Use Disorders, including Alcohol Use Disorder. We plan to focus initially on AUD, and, to that end, we signed an agreement with Psylabs to be the exclusive supplier of highly purified psilocybin extract exclusively for these indications. SUDs represent a significant burden to society, with as many as 44.4 million people aged 18 and over in the U.S. alone diagnosed with an AUD or SUD in 20211. Numerous prior academic studies suggest that psilocybin, when combined with psychotherapy, can be a safe and effective treatment option for these individuals - something that we aim to confirm in rigorously designed clinical studies. Staying on the topic of AUD for a moment, to further bolster our development efforts, we signed a conditional binding term sheet for the acquisition of psilocybin-based drug developer Clairvoyant. This acquisition, when completed, makes strategic sense for Psyence for several reasons. First, it introduces a synthetic psilocybin-based therapeutic candidate that nicely complements our ongoing nature-derived psilocybin development programs. Additionally, it efficiently expands our pipeline into AUD - a high-value indication - with a regulatory pathway that, if successful, will transition us to a commercial-stage, revenue-generating company. Clairvoyant is currently executing a Phase IIb clinical trial in AUD, with topline data expected in early 2025. Closing of this acquisition is contingent upon the completion of due diligence and customary closing conditions. Together, these initiatives give us line-of-sight to two critical Phase IIb data readouts, in two separate indications, in the relative near-term: first, data from Clairvoyant's ongoing trial in AUD in early 2025, followed by results from our trial in Adjustment Disorder in the second half of 2025. Finally, to ensure that we have the critical funding required to advance these initiates, we entered into agreements that are expected to provide us with sufficient capital to execute our strategy as outlined above. In closing, by announcing our second indication and strengthening our pipeline and supply chain, we continue our journey to become a fully-fledged, vertically integrated life science biotech company. While conditions in the capital markets continue to be challenging, we believe that our many accomplishments over these past months position us to be a leader in the rapidly emerging field of psychedelic-based therapeutics development for mental health and related disorders."

07:35 EDT Hyzon Motors announces start of production of Class 8 200kW FCET - Hyzon announced the Start of Production of its innovative Class 8 200kW Fuel Cell Electric Truck. This milestone signals that through its collaboration with North Carolina-based Fontaine Modification, the company can now begin production of its 200kW FCET. With the finalization of its first 200kW Class 8 vehicle built using production parts and processes, Hyzon's Class 8 truck platform now transitions from prototype to series production. This milestone comes as Hyzon expects to declare SOP on its unique single stack 200kW Fuel Cell System at its Bolingbrook facility - one of the largest fully-integrated fuel cell systems production facilities in the United States and the only 200kW plus single-stack fuel system to be launched into serial production - in the next few weeks. As part of the development of the FCET, Hyzon has arranged for Fontaine Modification to perform vehicle assembly and production in Charlotte, North Carolina. Hyzon provides Fontaine with kits for the fuel cell system, battery packs, and hydrogen storage systems. Fontaine assembles these into vehicle chassis, ensuring each truck is road ready. As part of the SOP, Fontaine has confirmed the necessary equipment, documentation, and processes are in place for series production.

07:34 EDT Bread Financial reports August net loss rate 7.8% vs 6.7% last year - Reports end-of-period credit card and other loans 17.936B vs 17.949B last year

07:33 EDT Wendy's names John Min as Chief Legal Officer and Secretary - The Wendy's Company announced the appointment of John Min as the company's Chief Legal Officer and Secretary and Mary Greenlee as Senior Vice President, U.S. Operations, effective September 16. These appointments represent the continued evolution of the company's leadership structure to drive accountability and accelerate growth. Min will report to President and CEO, Kirk Tanner, and Greenlee will report to President, U.S., Abigail Pringle. Min succeeds E.J. Wunsch, who was appointed as Wendy's President, International in June 2024.

07:32 EDT Jazz Pharmaceuticals presents updated Phase 2 data for zanidatamab - Jazz Pharmaceuticals announced updated data, including median progression-free survival and overall survival findings, from the Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy as first-line treatment for patients with HER2-expressing advanced or metastatic gastroesophageal adenocarcinoma. Data from 41 patients with HER2-positive mGEA who were treated with zanidatamab in combination with physician's choice of chemotherapy treatment demonstrated a mPFS of 15.2 months. After a median duration of follow-up of 41.5 months, the median OS was not mature, a Kaplan-Meier-estimated 24-month OS was 65% and the 30-month overall survival was 59%. "The updated results from this Phase 2 trial reaffirm zanidatamab's potential as a foundational treatment for patients with HER2-positive mGEA and showcase the promise of this HER2-targeted bispecific antibody to treat HER2-expressing cancers," said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals. "We look forward to continuing to advance our broader clinical development program for zanidatamab in GEA, including the Phase 3 first-line clinical trial HERIZON-GEA-01 that is expected to read out in the second quarter of 2025, and other HER2-expressing solid tumors, with the goal of supporting more patients with HER2-positive cancers."

07:28 EDT Tharimmune acquires global license, partners with Intract Pharma - Tharimmune has entered into a definitive agreement with Intract Pharma to exclusively license INT-023/TH023, an oral anti-tumor necrosis factor-alpha monoclonal antibody, infliximab. This strategic partnership aims to expand Tharimmune's therapeutic pipeline and reinforce its commitment to pioneering novel treatments for autoimmune diseases. Under the terms of the agreement, Tharimmune licensed global development and commercialization rights to Intract Pharma's Soteria and Phloral(R) delivery platform along with an existing supply agreement for infliximab to be used in the oral product development program. Intract Pharma received an upfront payment and is eligible to receive additional payments upon an equity financing of the Company and is eligible for future development, regulatory and commercial milestones, as well as mid-single digit royalties based on net product sales. The agreement retains a right of first refusal to continue development and commercialization after a Phase 2 clinical trial. In addition, Tharimmune has the option to exercise the license to Intract's platform for up to four additional targets. Infliximab is a purified, recombinant DNA-derived chimeric IgG monoclonal antibody protein that contains both murine and human components that inhibit TNF-alpha. Tumor necrosis factor-alpha is a signaling protein involved in acute phase reactions and systemic inflammation. Infliximab is sold by Janssen Biotech under the Remicade brand for numerous indications including Crohn's disease, ulcerative colitis, rheumatoid diseases and plaque psoriasis. Traditionally administered through intravenous infusions, oral delivery of antibodies such as infliximab is challenging due to the complexity of navigating such large molecules through the gastrointestinal tract. This new partnership aims to overcome these challenges using Intract's delivery platform, making it possible to administer infliximab in a pill form. An oral route of administration holds potential to improve patient compliance and quality of life, while also reducing the burden on the healthcare system associated with long-term intravenous therapy. This partnership enables the targeted delivery of antibody therapeutics directly to the colon or small intestine. By leveraging Intract's platform, Tharimmune aims to enhance the effectiveness of TNF-alpha inhibitors such as infliximab through precision delivery that maximizes proteolytic stabilization and tissue permeation. This novel approach offers significant potential for directly addressing inflammatory conditions within the gastrointestinal tract, including inflammatory bowel disease, as well as systemic inflammatory disorders where TNF-alpha plays a critical role in disease progression.

07:23 EDT Gilat Satellite awarded over $5M in support of U.S. Department of Defense - Gilat Satellite Networks announced that its wholly owned US-based subsidiary, DataPath, received contracts in support of the US Department of Defense for core terminal related services, technology insertion and upgrades to systems, cumulatively worth over $5M. DataPath is tasked with the sustainment and technical upgrades to multiple Satellite Transportable Terminal units to enhance these critical assets and the effectiveness of military operations.

07:23 EDT Gauzy to unveil next generation AI-powered ADAS for commercial trucks - Gauzy will be unveiling the first generation of its AI-powered advanced driver assistance system exclusively for commercial trucks at IAA TRANSPORTATION 2024, which takes place from September 17 - 22, 2024 at the Deutsche Messe AG venue in Hannover, Germany. Gauzy's ADAS for commercial trucks, which Ford Trucks has chosen to integrate into select vehicles, will allow the Company to generate additional revenue from its Safety-Tech division by capitalizing on the strong and growing demand for its innovative Smart-Vision camera monitor system that improves safety and fleet efficiency and reduces fuel consumption in the global commercial trucking industry, valued at more than $2.2 trillion. Gauzy's Smart-Vision CMS enables commercial truck operators to have increased visibility of the road from multiple vantage points by eliminating blind spots; it also is programmed to send drivers real-time notifications to enable them to make smarter and safer decisions. The system, which seamlessly integrates with any commercial truck model or trailer, replaces rear-, front- and side-view mirrors with high-quality interior displays and high-definition cameras affixed to the exterior of commercial trucks, providing drivers with a wider, less restricted view of their surroundings for easier maneuvering and higher accuracy when backing up and parking.

07:21 EDT Can-Fite received approval from Israeli MoH to conduct Phase IIa trial - Can-Fite BioPharma announced that it received approval from the Israeli Ministry of Health, MoH, to conduct Phase IIa clinical trial with orally-administered Namodenoson in the treatment of pancreatic carcinoma. "We are very much encouraged by the excellent data in the pre-clinical studies demonstrating the impressive anti-cancer effect of namodenoson and definitive molecular mechanism of action against pancreatic carcinoma," stated Dr. Fishman, Can-Fite's Chief Scientific Officer and Executive Chairman. "We are very keen to initiate the study in this devastating disease and are pleased with the regulatory approval of the Israeli MOH. We do hope that as we have shown efficacy in patients with advanced liver cancer studies, we will be able to demonstrate safety and efficacy in the pancreatic cancer patient population."

07:19 EDT Mercury expands portfolio of Direct RF digital signal processing products - Mercury Systems announced the expansion of its portfolio of Direct RF digital signal processing products that use Altera Agilex FPGAs to detect and process emissions from a wide portion of the electromagnetic spectrum. Direct RF components and modules directly digitize radio frequency signals at the antenna signal frequency, eliminating the analog signal down conversion stages required by legacy hardware. This approach requires extremely fast converters, high-bandwidth digital data links, and powerful real-time digital signal processing. The results are reductions in size, weight, power, cost, and latency that can benefit a variety of radar, communications, electronic warfare, SIGINT, and industrial applications.

07:17 EDT Kratos Defense awarded multi-million dollar contract from Thaicom Public Co - Kratos Defense & Security Solutions announced that Thaicom Public Company awarded Kratos a contract for its end-to-end ground system. The ground system will enable Thaicom to configure the satellite and ground system in tandem to deliver services to customers on demand optimizing the advanced features of its new software-defined satellite, THAICOM-10.

07:15 EDT Nayax announces long-term strategic partnership with Adyen - Nayax and Adyen announced a long-term strategic partnership to drive the seamless global delivery of cashless payment technology to businesses in the Electric Vehicle charging and automated self-service industries. With this partnership, Adyen joins Nayax's network of acquiring banks and Nayax's end-to-end payment and loyalty platform will be integrated into Adyen's single global platform. This allows Nayax to expand into new regions such as Latin America and APAC, while also significantly lowering operational costs associated with ongoing operations as a payment facilitator and entering into new markets.

07:12 EDT AstraZeneca announces HIMALAYA trial demonstrated overall survival benefit - Updated results from the HIMALAYA Phase III trial showed AstraZeneca's Imfinzi plus Imjudo demonstrated a sustained, clinically meaningful overall survival, or OS, benefit at five years for patients with unresectable hepatocellular carcinoma, or HCC, who had not received prior systemic therapy and were not eligible for localized treatment. These results from HIMALAYA will be presented today at the European Society for Medical Oncology, or ESMO, Congress in Barcelona, Spain. At five years of follow-up, this latest exploratory analysis showed that a single priming dose of Imjudo added to Imfinzi, called the STRIDE regimen, reduced the risk of death by 24% compared to sorafenib. An estimated 19.6% of patients treated with the STRIDE regimen were alive at five years versus 9.4% for those treated with sorafenib. In a subgroup analysis of patients in the trial who achieved disease control, defined as complete or partial response or stable disease, 28.7% of those treated with the STRIDE regimen were alive at five years versus 12.7% of patients treated with sorafenib. In addition, an exploratory analysis of depth of response, or DpR showed that more patients treated with the STRIDE regimen experienced deep responses leading to longer survival compared to sorafenib. The safety profile of the STRIDE regimen was consistent with the known profiles of each medicine, and no new safety signals were observed with longer follow-up. Serious treatment-related adverse events, defined as Grade 3 or 4 and including death, were experienced by 17.5% of patients treated with the STRIDE regimen versus 9.9% of patients treated with sorafenib, with no new events occurring after the primary analysis for STRIDE. Imfinzi in combination with Imjudo is approved for the treatment of adults with advanced or unresectable HCC in the U.S., EU, Japan and several other countries. Imfinzi monotherapy is also approved in Japan in this setting.

07:11 EDT Stingray Group launches Stingray Karaoke in Nio vehicles across Europe - Stingray (STGYF) announced the launch of Stingray Karaoke in NIO's (NIO) smart electric vehicles across European territories. This exciting new feature will be available in all NIO cars sold in Europe over the next two years, with each vehicle enjoying three years of complimentary karaoke service. As NIO enhances its presence in the European market, the partnership with Stingray introduces Karaoke, a distinctive feature designed to enrich the in-car experience. Stingray Karaoke offers an extensive library of songs across various genres and languages, catering to a diverse audience. Users can easily search for tracks by title, artist, lyrics, era, or genre. The service features a wide array of musical styles including Rock, Country, Pop, R&B, Latin, K&J Pop, and tunes suitable for family enjoyment, ensuring a rich selection that appeals to all ages.

07:09 EDT InspireMD submits premarket approval application for CGuard Prime system - InspireMD has submitted a Premarket Approval application to the U.S. Food and Drug Administration seeking marketing approval for the CGuard Prime carotid stent system in the U.S. The PMA application is based on the overwhelmingly positive one-year data from the Company's C-GUARDIANS pivotal clinical trial that were presented at the Leipzig Interventional Course 2024 in May. The C-GUARDIANS clinical trial evaluated the safety and efficacy of CGuard for the treatment of carotid artery stenosis. The study enrolled 316 patients across 24 trial sites in the U.S. and Europe. The C-GUARDIANS results showed a primary endpoint major adverse event rate of 1.95% through twelve months post-procedure, the lowest such event rate reported for any carotid stent or embolic protection device pivotal trial to date.

07:08 EDT Voyager advances Neurocrine collaboration, selects third gene therapy candidate - Voyager Therapeutics (VYGR) announced that the joint steering committee with its collaborator Neurocrine Biosciences (NBIX). has selected a development candidate in a gene therapy program for the potential treatment of an undisclosed neurological disease. The candidate leverages an intravenously administered, blood-brain barrier-penetrant, novel capsid derived from Voyager's TRACER capsid discovery platform. Selection of the development candidate triggered a $3 million milestone payment to Voyager, which the Company expects to receive in the fourth quarter of 2024. Voyager is eligible to receive additional future development and commercialization milestone payments based on the further advancement of this program. This program is being developed under the 2023 strategic collaboration agreement between Voyager and Neurocrine Biosciences for research, development, manufacture, and commercialization of certain AAV gene therapy products for programs targeting Parkinson's disease and other GBA1-mediated diseases and three other undisclosed programs. Under the terms of the 2023 collaboration agreement, for each of the three undisclosed programs, Voyager is eligible to receive up to $175 million in potential development milestone payments plus substantial potential commercial milestone payments, as well as tiered high single-digit to mid-teens royalties on U.S. net sales and mid-single-digit to low double-digit royalties on ex-U.S. net sales. Neurocrine Biosciences will fund the development of each program.

07:06 EDT EyePoint reports inducement grants under NASDAQ listing rule - EyePoint Pharmaceuticals announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 43,000 shares of EyePoint Pharmaceuticals common stock to two new employees. The stock options were granted on September 13, 2024. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $9.10 per share, the closing price of EyePoint Pharmaceuticals' common stock on September 13, 2024. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee's continued service with EyePoint Pharmaceuticals through the applicable vesting dates.

07:05 EDT Tonix announces single dose of TNX-801 aligns with WHO Preferred TPP - Tonix Pharmaceuticals announced that the World Health Organization's preferred target product profile, released at the WHO sponsored Mpox Research and Innovation Scientific Conference held August 29-30, 2024, aligns with the characteristics of TNX-801 vaccine, which is being developed for preventing mpox. Key elements of the WHO draft TPP include single-dose, durable protection, administration without special equipment, and stability at ambient temperature. Other potential beneficial characteristics include the ability to limit forward transmission, use in case-contact vaccination strategies and suitability for use in immunocompromised individuals. "The characteristics of TNX-801 align with the draft TPP released at the WHO sponsored Mpox Research and Innovation Scientific Conference," said Seth Lederman, M.D., Chief Executive Officer of Tonix. "In animal studies TNX-801 has shown single dose protection against a lethal challenge of Clade I monkeypox virus administered by intratracheal route.5 In addition, protected animals did not produce any infectious virus suggesting TNX-801 has the potential to block forward transmission as expected with live-virus vaccines. TNX-801 is designed for percutaneous administration using a bifurcated needle, like the products and delivery used in WHO's accelerated smallpox eradication project. Since TNX-801 is a live-virus vaccine, we expect the stability of lyophilized TNX-801 at ambient temperature to be similar to live vaccinia virus vaccines including ACAM2000. We believe TNX-801 can be shipped and stored without the need for a costly and cumbersome ultra-cold supply chain, a particular advantage in lesser developed parts of the world. The stability of live virus vaccines eliminates the need for ultra-cold storage which complicates the widespread use of mRNA vaccines in Africa, where they are needed most right now. Finally, studies on immunocompromised animals6 suggest that TNX-801 may be given to persons with immunocompromising conditions such as HIV, which is another property that will be essential for public health. The recent WHO declaration of a Public Health Emergency of International Concern underscores the urgent need for new vaccines to control this outbreak and save lives. We have been motivated to develop TNX-801 because single-dose vaccines simplify logistics of administration, achieve higher coverage by reducing vaccinee dropout between doses and allow for case-contact or "ring" strategies to vaccinate the contacts of confirmed mpox patients. Ring vaccination is deemed essential for controlling mpox but requires single-dose vaccines that interrupt forward transmission."

07:04 EDT Gogo, Airshare announce multi-year inflight connectivity agreement - Gogo Business Aviation and Airshare, one of the fastest-growing private aviation operators, have entered a multi-year inflight connectivity agreement that provides Airshare aircraft management clients an option to install Gogo AVANCE, Gogo 5G, and Gogo Galileo, the company's Low-Earth-Orbit broadband satellite service. The agreement continues a long-standing partnership between Gogo and Airshare, in which 65% of its Phenom 300 aircraft have already been upgraded to Gogo AVANCE with plans to upgrade the remaining fleet in the next 12 months.

07:03 EDT Green Thumb Industries announces $50M share repurchase program - Green Thumb Industries announced that its Board of Directors has authorized a $50 million share repurchase program. The repurchase program authorizes, pursuant to a normal course issuer bid, the repurchase of up to 10,573,860 of its Subordinate Voting Shares from time to time over the next 12 months. Under the Company's previous repurchase program that expired on September 10, 2024, Green Thumb repurchased 6.5 million shares for $73.3 million.

07:02 EDT Zentalis announces FDA lifted partial hold on azenosertib studies - Zentalis Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has lifted the partial clinical hold on studies of azenosertib, the Company's novel, selective, and orally bioavailable inhibitor of WEE1. The FDA has cleared the Company to resume enrollment in all ongoing azenosertib clinical studies with no changes in the clinical development plan. Zentalis will be working with clinical trial investigators to resume study activities across the azenosertib development program as quickly as possible.

06:56 EDT Aecom appointed to Northern Ireland Water's Professional Services Framework - Aecom announced that it is one of the companies that have been appointed by Northern Ireland Water to deliver asset management, design, site supervision, program and project management services on its IF182 Professional Services Framework, supporting projects from inception through delivery. AECOM has been appointed to two lots on the Framework, which is designed to help realize NI Water's ambitious capital programs that will provide sustainable water and wastewater solutions. As a Lot 1 Framework supplier, Aecom will deliver civil and mechanical, electrical, instrumentation, control and automation site supervision services. As a Lot 3 Framework supplier, Aecom will offer support on feasibility, design, project management and climate change management services.

06:53 EDT AstraZeneca announces updated results from HIMALAYA Phase III trial of Imjudo - Updated results from the HIMALAYA Phase III trial showed AstraZeneca's Imfinzi plus Imjudo demonstrated a sustained, clinically meaningful overall survival benefit at five years for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localised treatment. These results from HIMALAYA will be presented today at the European Society for Medical Oncology, ESMO, Congress 2024 in Barcelona, Spain. At five years of follow-up, this latest exploratory analysis showed that a single priming dose of Imjudo added to Imfinzi, called the STRIDE regimen, reduced the risk of death by 24% compared to sorafenib. An estimated 19.6% of patients treated with the STRIDE regimen were alive at five years versus 9.4% of those treated with sorafenib. In a subgroup analysis of patients in the trial who achieved disease control, defined as complete or partial response or stable disease, 28.7% of those treated with the STRIDE regimen were alive at five years versus 12.7% of patients treated with sorafenib. In addition, an exploratory analysis of depth of response showed that more patients treated with the STRIDE regimen experienced deep responses leading to longer survival compared to sorafenib.

06:50 EDT Novartis announces updated analysis from Phase III NATALEE trial - In an updated analysis from the pivotal Phase III NATALEE trial, investigational Kisqal added to endocrine therapy shows a deepening benefit beyond the three-year treatment period, reducing the risk of recurrence by 28.5%, compared to ET alone, in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer. This invasive disease-free survival benefit was also consistent across all pre-specified patient subgroups, including those with node-negative disease. Late-breaking data from this four-year post-hoc analysis will be presented today at the European Society for Medical Oncology, ESMO, Congress 2024. Results were also consistent across secondary efficacy endpoints, including distant disease-free survival, with a trend for improvement in overall survival

06:45 EDT Summit Therapeutics to explore further clinical development of ivonescimab - Summit Therapeutics announced that data for the novel, potential first-in-class investigational bispecific antibody, ivonescimab, was presented at the 2024 European Society for Medical Oncology Annual Meeting in Barcelona, Spain, including two presentations and one poster featuring updated ivonescimab data in advanced triple-negative breast cancer, recurrent / metastatic head and neck squamous cell carcinoma, and metastatic microsatellite-stable colorectal cancer. Each trial from which the data was generated was a Phase II study conducted in China sponsored by Akeso Inc. with data generated and analyzed by Akeso. Based on the results of these Phase II data sets as well as data announced earlier in 2024, including early-stage non-small cell lung cancer and biliary tract cancer, Summit intends to explore further clinical development of ivonescimab in solid tumor settings outside of metastatic non-small cell lung cancer, the company's current area of focus in its Phase III clinical trials.

06:33 EDT AdvanSix awarded $12M grant from USDA - AdvanSix announced that it has been awarded an approximately $12M grant from the U.S. Department of Agriculture through the Fertilizer Production Expansion Program supporting the expansion of innovative American fertilizer production strengthening domestic supply chains of fertilizers, and creating economic opportunities for American businesses. Through this grant, AdvanSix will further advance its Sustainable U.S. Sulfate to Accelerate Increased Nutrition initiative at its site in Hopewell, VA where ammonium sulfate fertilizer is currently produced. SUSTAIN is a series of projects with multi-year investments from AdvanSix which is targeting no net increase in energy consumption or emissions. These projects are designed to build on the facility's nearly 100-year history of providing a reliable, domestic supply of essential nitrogen-based fertilizers, while also keeping environmental stewardship at its core.

06:10 EDT Mawson Infrastructure provides operational highlights for August - Unaudited financial and operational highlights for August 2024: Digital Colocation Monthly Business Revenue up 166% Y/Y and up 25% M/M to $3.43M. Overall Monthly Revenue up 27% M/M from July 2024 to about $4.44M. Energy Management Monthly Business Revenue of $0.79 million and Self Mining Bitcoin Monthly Business Revenue of $0.22M. Expanded into AI and HPC (high-performance computing) colocation markets. Recently executed an AI / HPC colocation agreement for 20 MW to colocate AI customer NVIDIA GPUs, Expected to Generate Cumulative Revenue Potential of $285M. Signed separate non-binding LOI with the AI / HPC colocation customer to potentially expand to 144 MW. Secured lease amendment on 24 MW facility in Ohio for an extended total term of 9 years, including elective options, through April 2033 and commenced construction on the 24 MW facility in Ohio, and extended lease on 120 MW facility in Midland, Pennsylvania expanding presence across Pennsylvania and Ohio, and the PJM market which is North America's largest competitive and deregulated wholesale power market. Mawson is inviting AI/HPC partners to discuss opportunities to collaborate on the deployment of NVIDIA GPUs and other high-performance and accelerated computing solutions.

06:05 EDT KBR awarded $140M Air Force task order - KBR announced it was awarded a 60-month cost-plus-fixed-fee recompete Information Analysis Center Multiple Award Contract, or IAC MAC, task order with an estimated value of $140M to provide operational safety, suitability, and effectiveness engineering tasks supporting the Air Force Life Cycle Management Center, or AFLCMC. As the U.S. Air Force's trusted partner, KBR will continue to perform research and analyses developing recommendations related to reliability, maintainability, quality, supportability, and interoperability, airworthiness, life cycle management, failure testing, and diminishing manufacturing sources and material shortages issues at Hill Air Force Base in Clearfield, Utah, and other U.S. Air Force locations. Under the terms of the contract, KBR will continue to actively assist the F-16, A-10 and T-38 System Program Offices on their digital transformation journeys under digital material management initiatives. The team will also continue providing system engineering and integration support for systems such as the A-10 Ground Collision Avoidance System, or GCAS, and the F-16's Secure Mission Data System, or SMDS, and JARVIS programs. KBR will develop prototypes for critical safety hardware, such as the T-38 Canopy Transparency, utilizing state-of-the-art rapid prototyping capabilities.

05:54 EDT Immatics collaboration with Bristol Myers ends due to portfolio prioritization - In addition, Immatics' (IMTX) collaboration with Bristol Myers Squibb (BMY) for the co-development of IMA401 has ended due to ongoing portfolio prioritization efforts within Bristol Myers Squibb. The existing collaboration and license agreement signed in December 2021 will terminate effective December 12. Thereafter, all IMA401 development and commercialization rights will be reverted to Immatics. Immatics is not obligated to refund Bristol Myers Squibb any part of the $150M upfront received under the collaboration and is not required to make any future milestone payments to Bristol Myers Squibb; the parties will engage in a wind-down period as stipulated under the collaboration agreement. Based on the terms of the agreement with Bristol Myers Squibb, Immatics has been responsible for conducting the ongoing Phase 1 clinical trial. Immatics intends to advance IMA401 further through clinical development. The next data update is expected in 2025.

05:43 EDT Masimo comments on contest for control of board - Masimo is sharing a summary of the core issues to consider in this contest for control of the Masimo board and urging stockholders to vote for only Masimo's director nominees, Joe Kiani and Christopher Chavez, on the updated gold proxy card. "For more than 35 years, the team at Masimo has poured our heart and soul into driving innovations for patients and value for stockholders. We have internalized our stockholders' feedback and we are changing - some of those changes have already been implemented and others are just around the corner, including the separation of our consumer business and expansion of our Board. This builds on the continued momentum we are driving across Masimo, as demonstrated by our strong second quarter results and recently announced strategic partnerships with companies such as Google and Qualcomm," said Joe Kiani, chairman and CEO of Masimo. "We urge you not to trust Quentin Koffey to control this company - he is not qualified, he has no strategic plan, and he is not worthy of being trusted with your investment. After Quentin Koffey repeatedly sought to undermine Masimo's progress, a federal court has now held Quentin Koffey in contempt and publicly confirmed that he has lied to stockholders and proxy advisory firms ISS and Glass Lewis. We deeply appreciate all of the time stockholders have spent with us to understand why this vote matters so much. There are just nine months until our next Annual Meeting when you will get to vote again on me and other non-Politan directors currently on the Board. Our interests are aligned with our stockholders', and we will not let you down."

05:36 EDT Exact Sciences announces data for CRC screening test - Exact Sciences announced performance data for its blood-based colorectal cancer, or CRC, screening test. Results show sensitivities of 88.3% for CRC and 31.2% for advanced precancerous lesions at specificity of 90.1% for negative samples confirmed by colonoscopy. Results were presented today at the European Society for Medical Oncology, or ESMO, Congress in an oral presentation titled, "Organ-specific performance of a multi-analyte, multi-cancer early detection (MCED) blood test in a prospectively-collected cohort." To optimize the final test algorithm, Exact Sciences designed a study to simulate the screening population in the United States and better predict real-world, prospective performance of a novel test. The study consisted of more than 3,000 blood samples, including approximately 2,900 blinded, prospectively collected samples from the pivotal BLUE-C study. This analysis was prespecified with the FDA and the samples will be excluded from the final clinical validation. The study also included more than 90 advanced precancerous lesions, the majority of which were prospectively collected, and 60 case-collected colorectal cancer samples. In the pivotal BLUE-C study results, performance degradation is expected for advanced precancerous lesion sensitivity and overall CRC sensitivity. Results of this study show the potential of a novel, highly discriminate blood-based panel of methylated DNA markers and an impactful, new marker class to detect advanced precancerous lesions and cancers at an attractive cost profile. The company will implement the innovative marker class on a new testing platform and complete additional analytical studies to support an FDA submission. BLUE-C results for Exact Sciences' blood-based CRC screening test are now expected in the first half of 2025. Exact Sciences plans to use these results to support an FDA submission and approval and to make the blood-based CRC screening test available broadly. If approved, the blood-based CRC screening test could provide another testing option for 60M unscreened people in the United States. It would be supported by Exact Sciences' commercial infrastructure and ExactNexus technology platform, making electronic ordering and resulting seamless for more than 350 health systems. The company also presented data from its multi-cancer early detection, or MCED, blood test, assessing organ-specific performance of methylation and protein biomarkers in a prospectively collected cohort of samples from its ASCEND 2 study. The analysis indicated an overall sensitivity of 54.8% with 98.5% specificity in cancers without standard-of-care screening options and 63.7% in the six most aggressive cancers with the shortest survival rates. These findings highlight the potential clinical value of using multiple biomarkers to detect various cancer types, including the most aggressive and those without recommended screening options.

05:21 EDT Penumbra secures CE Mark in Europe for Lightning Flash 2.0, Lightning Bolt 7 - Penumbra announced it has secured CE Mark in Europe for the latest computer assisted vacuum thrombectomy, or CAVT, technologies - Lightning Flash 2.0 and Lightning Bolt 7.

05:14 EDT Stratasys announces $50M share repurchase program - Stratasys announced that its board of directors has authorized a share repurchase program allowing for the repurchase of up to $50M of its ordinary shares. The authorization is part of a number of strategic actions the company is taking to build upon its previously announced restructuring plan designed to maintain its industry leadership and better align with evolving market conditions. Stratasys' previously announced restructuring efforts are expected to produce approximately $40M in annual cost savings beginning in the first quarter of 2025. These initiatives include rightsizing the company's workforce by approximately 15% by the end of the year and enhancing its go-to-market strategy to focus on the highest growth potential products, materials and software solutions. In addition to these restructuring efforts, the Company continues to focus on operational improvements, efficiencies and asset optimization, including monetizing underutilized assets, to further strengthen its balance sheet and drive cash generation.